Compared with the CON group, serum OCN and BALP activities in the T2DM group were significantly reduced (P < 0.05; Fig. 6A, B); however, genistein administration inhibited the reductions of OCN and BALP. This evidence concerns the gene BGLAP and type 2 diabetes mellitus.